Ask a 3M Biopharma Expert

All fields are required unless indicated optional.

  • Enter your 10-digit phone number. Numbers only (5555555555).

3M will use the information to respond to your request and in accordance with our Privacy Policy.



3M takes your privacy seriously. 3M and its authorized third parties will use the information you provided in accordance with our Privacy Policy to send you communications, which may include promotions, product information and service offers.


Loading wheel

Thank you for contacting us! Logo
Thank you!

Your request has been submitted successfully. A representative will contact you shortly.

Sorry Logo

Sorry!

We can’t seem to complete your request. Please try again.

Stay connected with industry expert news. We’ll keep you up to speed on innovative material science technologies.

To join our email subscription, please enter the following:

  • All fields are required

  • 3M takes your privacy seriously. 3M and its authorized third parties will use the information you provided in accordance with our Privacy Policy to send you communications which may include promotions, product information and service offers. Please be aware that this information may be stored on a server located in the U.S. If you do not consent to this use of your personal information, please do not use this system.

  • Submit

Our apologies...

An error has occurred while submitting. Please try again later...

Thank you for subscribing

Strand of DNA.

Gene Therapy

  • Biopharmaceutical scientist stationed at a trinocular microscope.

    Gene therapy clarification.

    Gene therapy presents some of the most anticipated opportunities for emerging drugs. With the help of these specialized medicines, the patient's body is converted into an agent to help fight diseases - ranging from cancers to central nervous system disorders and musculoskeletal conditions.​

     

    Adeno-associated viruses (AAVs) are often used to deliver genetic materials to target cells to treat or prevent inherited genetic disorders such as hemophilia A or sickle cell anemia. As industry’s understanding of cell biology has improved, vector-directed gene therapy has emerged as an important future drug modality, similar to the adoption of recombinant proteins in the early 2000s.​

     

    Gene therapy drugs using AAV are made in bioreactors in cells such as human embryonic (HEK) cells, similar to how recombinant protein therapies are made. 3M biopharma filtration and purification products can potentially be used in the manufacturing processes of gene therapy drugs using AAV as viral vector.​

     

    ​Our Bioprocessing Application Specialists can guide you through manufacturing challenges and bottlenecks to develop efficient processes from pre-clinical to commercial scales.

     

    Learn how we can help


Reimagine harvest and push the boundaries of clarification with anion-exchange (AEX) fibre chromatography.

Infographic illustrating the steps from AAV lysate to the sterilizing filter.
  • Clarification is a critical unit operation in the production of biologics because it directly affects yield, product consistency and performance of downstream unit operations. 3M created a novel clarification method by filtering with charge rather than by particle size. The media is designed with a synthetic nonwoven material containing quaternary amine grafted fibres, which can remove more impurities than traditional depth filters. ​

     

    ​Large contaminants such as cells and cell debris, plus small insoluble and soluble impurities like DNA and HCP, can be removed at this early stage. Enabling higher purity earlier in the clarification steps makes the following downstream processing easier.​


  • CHO cells shown on the surface of the product fibre bed.

    Filtering with charge rather than particle size.

    Viewed with a scanning electron microscopy (SEM), cells can be seen adsorbed and captured throughout the matrix of the functional nonwoven bed of 3M™ Harvest RC Chromatographic Clarifier.

    3M™ Harvest RC Chromatographic Clarifier

    Technology Platforms

    • Quaternary amine (Q) functionalized polypropylene nonwoven
    • 0.2 μm polyether sulfone (PES) membrane

    Mechanism

    • AEX

    Materials

    • Synthetic

    Feed Stream

    • Direct harvest

Experience 3M innovation from lab to production scale.

Learn More

From lab scale to commercial manufacturing, we can help streamline and accelerate your workflow with the entire 3M™ Harvest RC Chromatographic Clarifier portfolio of innovative solutions that enable you to condense steps and improve process efficiencies.

  • Lab scale chromatographic clarifier products.
    Discovery Phase Solutions

    Start your discovery process with lab scale solutions that enable you to do your job in less time with less complexity.

  • Variety of production scale chromatographic clarifier capsules.
    Production Scale Solutions

    Advance from lab to production scale with the 3M™ Harvest RC Chromatographic Clarifier portfolio of lab and manufacturing capsules.


Variety of different sized encapsulated filter capsules.

3M™ Zeta Plus™ Encapsulated System Filter Capsules

  • Depth filters use fibrous filtration media to retain particles throughout the media, rather than just on the media surface. They are commonly used when process fluid contains a high particle load because, relative to other types of filters, they can retain a large mass of particles before becoming clogged.

Infographic of encapsulated depth filtration products from AAV lysate to sterilizing filter.
  • Depth filtration has been the most prevalent single-use clarification technology in many biopharmaceutical manufacturing processes. 3M offers easy-to-handle depth filter solutions in a variety of nominal pore sizes and media characteristics to fit your process needs.​


  • Four 3M™ bioprocessing application specialists posing as a group.

    Global engineering, delivered by specialists.

    3M’s Bioprocessing Application Specialists can provide guidance to navigate process challenges and resolve inefficiencies to achieve commercial scale. They can identify a common platform that scales from lab to full production and look for opportunities for process intensification — removing unnecessary steps, combining several steps into one and increasing throughput and capacity.​

    3M is leveraging its current product portfolio to design AAV clarification processes today while developing innovative solutions to enable the AAV clarification processes of tomorrow. Contact 3M to learn how we can support your current needs.

Ask an expert

Fill out this form for any technical, business or process-related question, and an appropriate 3M Biopharmaceutical representative will contact you to answer your question or direct your request. ​

Request a trial

Fill out this form and a 3M Biopharmaceutical representative will contact you to help you select and receive a sample or trial based on your needs.


Explore Solutions

All products

Explore Applications

  • One step can transform your mAb and recombinant protein manufacturing process. At 3M, we’re helping build better, more efficient and simpler manufacturing processes by developing solutions to enhance biologic drug recovery that leads to improved process economics.​

  • Plasma fractionation has existed for decades, but additional separation methods are becoming increasingly common. We offer a range of products to help you with your process.

  • Getting the most out of your manufacturing process with speed and on budget is an increasing challenge. Our solutions may help you develop manufacturing processes for vaccines to help maximize purity, leading to overall process economics.​

  • If you need solutions for catalyst removal and recovery, colour removal, particulate filtration and fill-finish, 3M offers a wide range of adsorptive depth filters and membrane products for application in the chemical pharmaceutical manufacturing.


Laptop displaying an online sign up forms for notifications.
Stay up to date on the latest news and product information.
SUBSCRIBE